Major Depressive Disorder (DSM-IV) – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of major depressive disorder (MDD) (DSM-IV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of MDD (DSM-IV) for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.
DRG Epidemiology’s MDD (DSM-IV) forecast will answer the following questions:
- Of all people with MDD (DSM-IV), how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with MDD (DSM-IV), how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDD (DSM-IV) over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts four key MDD (DSM-IV) patient populations, as follows:
- Total prevalent cases.
- Diagnosed prevalent cases.
- Drug-treated prevalent cases.
- Treatment-resistant drug-treated prevalent cases.
Note: Coverage may vary by country.
Table of contents
- Major Depressive Disorder (DSM-IV) - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Total 12-Month Prevalence of Major Depressive Disorder per 1,000 People Aged 15+ in 2021 and 2041ttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Total 12-Month Prevalent Cases of Major Depressive Disorder over the Next 20 Yearsttttttttt
- Epidemiology Data
- Methods
- 12-Month Prevalent Cases of Major Depressive Disorder (DSM-IV)
- 12-Month Prevalent Cases of Major Depressive Disorder with Chronic Pain
- 12-Month Prevalent Cases of Chronic Major Depressive Disorder
- 12-Month Prevalent Cases of Major Depressive Disorder with Anxiety Disorders
- Diagnosed Prevalent Cases of Major Depressive Disorder
- Drug-Treated Prevalent Cases of Major Depressive Disorder
- Diagnosed Prevalent Cases of Treatment Resistance Among Drug-Treated Prevalent Cases of Major Depressive Disorder
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Major Depressive Disorder (DSM-IV)
- Studies Excluded from the Analysis of Major Depressive Disorder (DSM-IV)
- Risk/Protective Factors
- Risk/Protective Factors for Major Depressive Disorder (DSM-IV)
- Bibliography
- Abbreviation
- Glossary
- Literature Review
- Introduction
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.